Biocartis Receives €1.4M to Support Development of Rapid NGS Prep Panels
News Nov 01, 2016
The NGS Prep Panels that Biocartis has under development combine the company’s best-in-class sample preparation technologies for oncology applications (such as FFPE1 tissue, cytological materials or plasma) integrated in the Idylla™ cartridge, with the generation of DNA libraries2 that contain a wide range of enriched genomic information relevant for oncology diagnostics. Both steps comprise the majority of the NGS workflow. As such, the NGS Prep Panels can function as a gateway to NGS by providing standardization and automation of key sample and library preparatory steps. This is expected to reduce the total hands-on and turnaround time of a standard NGS workflow with 50%-75%3 and will significantly reduce workflow errors given, amongst others, the high level of automation.
While the Idylla™ qPCR4 technology is ideally suited for fast and cost-effective first-line detection of the most common pre-identified cancer driving gene alterations, NGS technology is capable of detecting a broader spectrum of gene alterations, which is particularly useful to detect less frequently occurring cancer-driving mutations. The NGS Prep Panels under development, from a health economic perspective, are as such a cost-efficient way to bridge these complementary technologies.
Nicolas Vergauwe, Head of Innovation at Biocartis, commented: “Once again, Biocartis is grateful for the financial support it has received from VLAIO. Thanks to this project, Biocartis can further expand the true platform capabilities of Idylla™ by the development of highly innovative NGS Prep Panels, complimentary to first-line rapid and highly accurate Idylla™ testing for the detection of the most common mutations. This will open doors to ensure that a larger population has access to the newest targeted cancer treatments via Idylla™ triaging, which is expected to improve treatment outcomes while lowering healthcare costs.”
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE